These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1511 related articles for article (PubMed ID: 20033812)
1. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812 [TBL] [Abstract][Full Text] [Related]
2. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335 [TBL] [Abstract][Full Text] [Related]
3. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897 [TBL] [Abstract][Full Text] [Related]
4. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX. Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872 [TBL] [Abstract][Full Text] [Related]
5. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. Garrity MM; Burgart LJ; Mahoney MR; Windschitl HE; Salim M; Wiesenfeld M; Krook JE; Michalak JC; Goldberg RM; O'Connell MJ; Furth AF; Sargent DJ; Murphy LM; Hill E; Riehle DL; Meyers CH; Witzig TE; J Clin Oncol; 2004 May; 22(9):1572-82. PubMed ID: 15117979 [TBL] [Abstract][Full Text] [Related]
7. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. des Guetz G; Mariani P; Cucherousset J; Benamoun M; Lagorce C; Sastre X; Le Toumelin P; Uzzan B; Perret GY; Morere JF; Breau JL; Fagard R; Schischmanoff PO Anticancer Res; 2007; 27(4C):2715-9. PubMed ID: 17695437 [TBL] [Abstract][Full Text] [Related]
8. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. Bertagnolli MM; Niedzwiecki D; Compton CC; Hahn HP; Hall M; Damas B; Jewell SD; Mayer RJ; Goldberg RM; Saltz LB; Warren RS; Redston M J Clin Oncol; 2009 Apr; 27(11):1814-21. PubMed ID: 19273709 [TBL] [Abstract][Full Text] [Related]
9. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738 [TBL] [Abstract][Full Text] [Related]
10. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX). Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study. Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026 [TBL] [Abstract][Full Text] [Related]
12. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Balaguer F; Sempere L; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Pons E; Payá A; Alenda C; Eur J Cancer; 2009 Feb; 45(3):365-73. PubMed ID: 18722765 [TBL] [Abstract][Full Text] [Related]
13. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator for adjuvant therapy in colon cancer. Kumar S; Chang EY; Frankhouse J; Dorsey PB; Lee RG; Johnson N Arch Surg; 2009 Sep; 144(9):835-40. PubMed ID: 19797108 [TBL] [Abstract][Full Text] [Related]
14. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Nehls O; Okech T; Hsieh CJ; Enzinger T; Sarbia M; Borchard F; Gruenagel HH; Gaco V; Hass HG; Arkenau HT; Hartmann JT; Porschen R; Gregor M; Klump B Br J Cancer; 2007 May; 96(9):1409-18. PubMed ID: 17426704 [TBL] [Abstract][Full Text] [Related]
15. Low microsatellite instability is associated with poor prognosis in stage C colon cancer. Kohonen-Corish MR; Daniel JJ; Chan C; Lin BP; Kwun SY; Dent OF; Dhillon VS; Trent RJ; Chapuis PH; Bokey EL J Clin Oncol; 2005 Apr; 23(10):2318-24. PubMed ID: 15800322 [TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. Kim GP; Colangelo LH; Wieand HS; Paik S; Kirsch IR; Wolmark N; Allegra CJ; J Clin Oncol; 2007 Mar; 25(7):767-72. PubMed ID: 17228023 [TBL] [Abstract][Full Text] [Related]
18. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer. Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521 [TBL] [Abstract][Full Text] [Related]
19. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]